Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 55,90
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 62,78
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Vendeur : California Books, Miami, FL, Etats-Unis
EUR 65,11
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Vendeur : Majestic Books, Hounslow, Royaume-Uni
EUR 60,31
Quantité disponible : 3 disponible(s)
Ajouter au panierEtat : New. pp. 525.
Vendeur : Books Puddle, New York, NY, Etats-Unis
EUR 65,16
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. pp. 525 1st edition NO-PA16APR2015-KAP.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 58,11
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
EUR 64,94
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. In.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 64,70
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
EUR 64,71
Quantité disponible : 1 disponible(s)
Ajouter au panierPaperback / softback. Etat : New. New copy - Usually dispatched within 4 working days.
Vendeur : Books Puddle, New York, NY, Etats-Unis
EUR 89,70
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 118,70
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Vendeur : Books Puddle, New York, NY, Etats-Unis
EUR 118,33
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. pp. 552.
Langue: anglais
Edité par Chapman and Hall/CRC 2014-11-14, 2014
ISBN 10 : 1482241390 ISBN 13 : 9781482241396
Vendeur : Chiron Media, Wallingford, Royaume-Uni
EUR 112,65
Quantité disponible : 5 disponible(s)
Ajouter au panierHardcover. Etat : New.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 115,57
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Vendeur : California Books, Miami, FL, Etats-Unis
EUR 136,38
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Langue: anglais
Edité par Apple Academic Press Inc., 2014
ISBN 10 : 1482241390 ISBN 13 : 9781482241396
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
EUR 131,36
Quantité disponible : 1 disponible(s)
Ajouter au panierHardback. Etat : New. New copy - Usually dispatched within 4 working days.
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
EUR 144,78
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. In.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 182,09
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : Revaluation Books, Exeter, Royaume-Uni
EUR 181,55
Quantité disponible : 2 disponible(s)
Ajouter au panierHardcover. Etat : Brand New. 400 pages. 9.25x6.25x1.25 inches. In Stock.
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
EUR 172,64
Quantité disponible : 1 disponible(s)
Ajouter au panierHardcover. Etat : Like New. Like New. book.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 205,05
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
EUR 67,19
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. PRINT ON DEMAND pp. 525.
Vendeur : AussieBookSeller, Truganina, VIC, Australie
EUR 62,60
Quantité disponible : 1 disponible(s)
Ajouter au panierHardcover. Etat : new. Hardcover. Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.
Vendeur : Majestic Books, Hounslow, Royaume-Uni
EUR 89,37
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. Print on Demand.
Vendeur : CitiRetail, Stevenage, Royaume-Uni
EUR 58,52
Quantité disponible : 1 disponible(s)
Ajouter au panierHardcover. Etat : new. Hardcover. Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
Vendeur : moluna, Greven, Allemagne
EUR 53,56
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Johan A.K. Suykens is a professor at Katholieke Universiteit Leuven, Belgium, where he obtained a degree in electro-mechanical engineering and a Ph.D in applied sciences. He has been a visiting postdoctoral researcher at the University o.
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
EUR 91,83
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. PRINT ON DEMAND.
Vendeur : Majestic Books, Hounslow, Royaume-Uni
EUR 120,61
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. Print on Demand pp. 552 This item is printed on demand.
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
EUR 122,22
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. PRINT ON DEMAND pp. 552.
Vendeur : preigu, Osnabrück, Allemagne
EUR 65,65
Quantité disponible : 5 disponible(s)
Ajouter au panierBuch. Etat : Neu. Headache Disorders | New Advances in Management and Treatment Strategies | Buch | Englisch | 2025 | MDPI AG | EAN 9783725843473 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.